Depression Advisor

Investigators found data that showed a ghrelinergic signaling mechanism may be responsible for increased appetite in patients with MDD.

Depression is a major contributor to the overall global burden of disease, with more than 300 million individuals suffering from depression.1 Yet, the limited scope of therapeutics for the condition has left patients with few treatment options and low rates of remission. This may change as progress is made on the pathophysiology of depression. Indeed,…

Researchers found that bright light therapy is a suitable option for those who must avoid antidepressant medications, such as individuals who are in perinatal and geriatric populations.

Major depressive disorder (MDD) is commonly observed in medical settings, with a prevalence of up to 14% compared with 2% to 4% in the general population.1 Various studies have found rates of 12% to 18% in patients with diabetes, 15% to 23% in those with coronary heart disease, 23% to 54% in patients with multiple…

Currently, there is an unmet need for the development of rapid-acting antidepressants aimed at treatment-resistant patients with either major depressive disorder (MDD) or bipolar disorder. A review of existing treatment options, as well as future possibilities, was published in Psychiatry and Clinical Neurosciences.1 Approximately 320 million people worldwide are affected by MDD, with a noted…